MS
BCRX icon

Maven Securities’s BioCryst Pharmaceuticals BCRX Stock Holding History

Maven Securities’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-90,000
Closed -$539K – 422
2023
Q4 		$539K Buy
+90,000
New +$522K 0.01% 644
2021
Q1 		– Sell
-65,000
Closed -$488K – 1170
2020
Q4 		$488K Buy
+65,000
New +$335K 0.05% 363
2020
Q3 		– Sell
-150,000
Closed -$714K – 611
2020
Q2 		$714K Buy
+150,000
New +$599K 0.05% 254
2020
Q1 		– Sell
-1,118,593
Closed -$3.65M – 319
2019
Q4 		$3.65M Buy
+1,118,593
New +$2.81M 0.33% 59

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return

Maven Securities's BCRX Position: Q1 2024 in Review

Maven Securities sold out of BioCryst Pharmaceuticals (BCRX) in Q1 2024, closing a stake of 90,000 shares — an estimated $539K sold.

Maven Securities first reported a position in BCRX in Q4 2019 and held it in 4 quarters. The position peaked at $3.65M in Q4 2019. 238 funds tracked by Wall St. Rank hold BCRX as of Q1 2024.

  • Maven Securities reported no remaining BioCryst Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Maven Securities sold 90,000 BioCryst Pharmaceuticals shares in Q1 2024, an estimated $539K.
  • Maven Securities first reported a position in BioCryst Pharmaceuticals in Q4 2019 and held it in 4 quarters.
  • Maven Securities's BioCryst Pharmaceuticals position peaked at $3.65M in Q4 2019.
  • 238 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2024.

Based on Maven Securities's 13F filing for Q1 2024, filed 14 May 2024.